Konorev DSA: Drugs for Diabetes Flashcards

1
Q

Rapid Acting Inulins

A
  • aspart
  • lispro
  • glulisine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

short acting insulins

A

-regular insulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Intermediate acting insulin

A

NPH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Long acting insulin

A
  • Detemir

- Glargine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Amylin analog

A

-Pramlintide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Insulin secretagogues

A
  • incretin memetics

- Katp channel blockers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Incretin Mimetics

A
  • GLP-1 agonists: Exenatide, Liraglutide

- Dipeptidyl peptidase-4 (DPP-4) inhibitors: Sitagliptin, linagliptin, saxagliptin, alogliptin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Katp channel blockers

A
  • sulfonylureas

- Meglitinides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

first generation sulfonylureas

A
  • Chorpropamide
  • tolbutamide
  • tolazamide
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Second generation Sulfonylureas

A
  • Glipizide
  • Glyburide
  • Glimepride
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Meglitinides

A
  • Nateglinide

- Repaglinide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Biguanides

A

Metformin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Thiazolidinediones

A
  • Pioglitazone

- Rosiglitazone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Sodium-glucose co transporter 2 (SGLT2) inhibitors

A
  • Canagliflozin
  • Dapagliflozin
  • Empagliflozin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Inhibitors of alpha-glycosidases

A
  • Acarbose

- Miglitol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the end effects of insulin?

A
  • increased glycogen/lipid/protein synthesis
  • decreased lipolysis
  • cell growth and differentiation
  • AKT pathway: regulation of enzyme activities
  • MAP kinases: regulation of gene trascription and cell proliferation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What transcription factor is for cell growth and differentiation and for cell proliferation and increased survival?

A

ELK1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Which TF is for cell growth and differentiation and cell proliferation and apoptosis

A

-AP-1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Which TF will give of decreased glycogenolysis, decreased gluconeogenesis, and escaped the cell cycle arrest and increases proliferation?

A

FoxO1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What happens with GLUT4 when insulin binds IRS?

A

gets translocated to the cell membrane

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are the effects on carb metabolism by Insulin?

A
  • glucose transport (GLUT4)
  • Activation of glycolysis
  • Activation of glycogen synthesis
  • Inhibition of gluconeogenesis
  • Inhibition of glycogenolysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Is cAMP lowered or elevated by insulin binding?

A

lowered

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Insulin effects on lipid metabolism

A
  • inhibition of lipolysis :decreased hormone-sensitive lipase, decreased TG breakdown
  • enhanced lipogenesis: increased expression of FA synthase
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Insulin effects on protein metabolism

A
  • increased ptn synth

- increased mTOR,,,, ribosome biogenesis, mRNA translation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Why are the rapid acting insulins so rapid?
-mutations fromhuman sequence block assembly of dimers and hexamers... allow for faster absorption
26
Clinical use of rapid-acting insulins
-postprandial hyperglycemia...taken before a meal
27
What is used for overnight coverage of insulin in the body?
- just regular insulin - if for postprandial hyperglycemia, inject 45 min before the meal - lasts 10 hrs
28
What is used for basal insulin maintenance and/or overnight coverage?
NPH, the intermediate acting insulin | -lasts 4-12 hrs
29
What is used for pretty much only basal insulin maintenance?
Long acting insulin: Detemir or Glargine | -lasts 24 hrs
30
Indications for insulin use?
Type 1 or 2 diabetes - or Severe Hyperkalemia, remember that it also traps all of the K+ in the cell - use loop diuretics to eliminate K+ from the body
31
Adverse effects of Insulin
- hypoglycemia - lipodystrophy - Resistance: they will develop insulin binding antibodies - Allergic rxns (rare) - hypokalemia
32
What is the most common complication of insulin therapy?
Hypoglycemia
33
Common causes of hypoglycemia
- delay of a meal or a missed meal - exercise: exercised muscle consumes more glucose - overdose of insuin
34
Signs of hypoglycemia
- confusion,m dizarre behavior, seizures, coma - sympathetic hyperactivity: tachycardia, palpitations, sweating, tremor - Parasympathetic hyperactivity: hunger, nausea - Patients on tight glycemic control: "hypoglycemic unawareness"
35
Tx for hypoglycemia
- glucose: juice, candy, etc. if consciou; I.V. glucose if unconscious - Diazoxide: stong hyperglycemic agent- Katp channel opener.... also inhibits the release of insulin by beta cells - Glucagon
36
MOA of Glucagon
- Gs coupled GPCR - activation of AC - PKA - phosphorylase.... glycogenolysis - increased expression of PEPCK and Glu-6-Pase.... gluconeogenesis
37
Effects of Glucagon
- Hepatocytes: increased glucose output, glycogen depletion (non of this nonsense in skeletal m.) - Potent inotropic and chronotropic effcet on the heart - GI smooth muscle relaxation - Increase insulin release by beta-cells - increase release of catecholamines by chromaffin cells (contraindicatedin pheochromocytoma patients)
38
Clinical uses of glucagon
- moderate-to severe hypoglycemia - beta-blocker overdose - Radiology of the bowel
39
Amylin analog
Pramlintide
40
What is pramlintide used for?
type 1 or 2 diabetes | -injected sc before meals as an adjunct to insulin therapy
41
Adverse effects of pramlintide
- GI: nausea, vomiting, diarrhea, anorexia | - Severe hypoglycemia, especially if used together with insulin... insulin dose should be reduced
42
Drug interactions with Pramlintide
-enhances effects of anticholinergic drugs in GI tract
43
What are the long acting GLP-1 receptor agonists?
- Exenatide | - Liraglutide
44
Clinical use of Exenatide or Liraglutide
- release of GLP-1 is diminished post prandially in type 2 diabetes pts - approved in type 2 diabetics not adequately controlled by metformin/sulfonylureas/thiazolidinediones - doses of other anti-diabetic meds should be reduced to avoid hypoglycemia
45
Adverse effects of GLP-1 receptor antagonists
- Nausea, comiting, diarrhea, anorexia - lower risk of hypoglycemia vs. pramlintide - linked to cases of acute pancreatitis and pancreatic cancer - possible link to thyroid cancer
46
What are the DPP-4 inhibitors?
- the gliptins - Sitagliptin - Linagliptin - Saxagliptin - Alogliptin
47
MOA of DPP-4 inhibitors?
- DPP-4 is a serine protease that degrades GLP-1 and other incretins - so... we stop that shit - used as adjunctive therapy w/ diet and exercise
48
Averse effects of the DPP-4 inhibitors
- upper respiratory infections and nasopharyngitis - linked to acute pancreatitis - hypoglycemia
49
Katp channel blockers
- sulfonylureas 1st and 2nd gen | - Non-sulfonylureas (meglitinides)
50
What's the difference between 1st and second generation sulfonylureas?
-2nd gen has higher potency
51
Clinical use of sulfonylureas
-type 2 diabetes as a monotherapy or in combo with insulin or other anti-diabetic drugs
52
adverse effects of sulfonylureas
- hypoglycemia - weight gain - secondary failure - Disulfiram-like effect of alcohol-induced flushing - Dermatological and general hypersensitivity reactions with other sulfonamides
53
Drug interactions with sulfonylureas that enhance their hypoglycemic effect
- displacing from binding with plasma proteins: sulfonamides, clofibrate, and salicylates - enhancing the effect on Katp channel: ethanol - inhibiting CYP enzymes: azole antifungals, gemfibrozil, cimetidine, etc..
54
Drug interactions with sulfonylureas that decrease their glucose-lowering effect
- inhibiting insulin secretion : beta-blockers, CCBs - antagonizing their effect on Kast channel: diaazoxide - Inducing hepatic CYP enzymes: phenytoin, griseofulvin, rifampin, etc.....
55
MOA of Meglitinides
-Katp Channel inhibitiion
56
clinical use of meglitinides
- control of postprandial hyperglycemia in patients with type 2 diabetes - taken orally before the meal - can be used either alone or in combo with other antidiabetic drugs
57
Side effects of meglitinides
- hypoglycemia - secondary failure - weight gain
58
Biguanides
Metformin!
59
MOA of metformin
- activation of AMP-dependent ptn kinase - exact mechanism unclear - Phophorylates stuff... leads to: inhibition of lipogenesis and gluconeogenesis, increase in glc uptake, glycolysis, and FA oxidation, lower glc levels in hyperglycemic (but not normoglycemic) states, increases insulin sensitivity
60
Clinical use of metformin
-most commonly used oral agent to treat type 2 diabetes*... first line
61
Why is metformin so great?
- does better job of lowering glucose - does not cause hypoglycemia - no weight gain - taken orally - can be used either alone or in combo w/ other oral agents
62
PK of metformin
- not bound to plasma proteins - not metabolized - excreted unchanged by kidneys
63
Adverse effects and contraindications of metformin
- most common: GI complications like anorexia, vomiting, nausea, diarrhea, abdominal discomfort - decreased absorption of B12 - lactic acidosis, especially under conditions of hypoxia, renal and hepatic insufficiency - contraindicated in conditions predisposing to tissue hypoxia, renal failure, chronic alcoholism, and cirrhosis
64
Thiazolidinediones
- Pioglitazone | - Rosiglitazone
65
MOA of thiazolidinediones
- Ligands of peroxisome proliferator-activated receptor-gamma (PPARy) - endogenous ligands: PG and FFAs and their derivatives - but TZDs have much igher affinity for PPARy
66
What is PPARy?
a nuclear receptor expressed primarily in fat, muscle, liver tissue, and endothelium -heterodimeric PPARy/RXR binds to specific DNA PPRE sequences to either increase or decrease gene transcription
67
What are the effects of PPARy activation on gene expression?
- increased GLUT4 in skeletal m.: enhanced glucose uptake, reduced hyperglycemia - same for adipocytes - increased IRS1,2, and PI3K: increased insulin sensitivity - Increased Adiponectin and other adipiokines: increased insulin sensitivity and decreased inflammation - decreases gluconeogenesis - decreases NFKB and AP-1 transactivation: decreased production of IL's and other cytokines... antiinflammatory
68
important PK thing for TZDs
- it's metabolized by the liver, so things that induce CYP will decrease its half life - safe to administer to patients with renal failure
69
clinical use of TZDs?
- type 2 diabetes - delays progression of prediabetes to type 3 diabetes - euglycemic drug.... no hypoglycemia when used alone
70
Adverse effects of TZDs
- weight gain, especially if with insulin - Edema: increased ENaC in kidneys - Exacerbation of heart failure - Link to the increased risk of bladder cancer - Osteoporosis - Increased TC and LDL-C (rosiglitazone
71
SGLT2 inhibitors
- Canagliflozin - Dapagliflozin - Empagliflozin
72
MOA of SGLT2 inhibitors
-inhibit the SGLT2 transporter, which lets us excrete some glucose into the urine... reduces hyperglycemia
73
Other effects of SGLT2 inhibitors
- osmotic iduresis - induces weight loss - reduces blood pressure - reduce plasma levels of uric acid - do not cause hypoglycemia when used alone
74
Clinical use of SGLT2 inhibitors
- as an adjunct to diet and exercise in adults with type 2 diabetes - taken orally before the first meal once a day - in pts with hypovolemia, this condition should be corrected before the start of therapy
75
Adverse effects of SGLT2 inhibitors
- hypotension - hypovolemia: dizziness, syncope - Genital and urinary tract infections - hypoglycemia if combined with insulin or insulin secretagogues - increased LDL-C - renal function impairment: fall inglomerular filtration rate, increase plasma creatinine - hyperkalemia - development of ketoacidosis
76
Alpha-glycosidase inhibitors
- Acarbose | - Miglitol
77
MOA of alph-glycosidase inhibitors
- competitive inhibition of a-glycosidases, a family of enzyme located on the brush border of intestinal epithelium - only monosaccharaides are absorbed from GI into the blood - Enzyme inhibition defer digestion and thus absorption of ingested starch and disaccharides - lower postprandial hyperglyemia to creat an insulin-sparing effect
78
Clinical use of alpha-glycosidase inhibitors
- type 2 diabetes as monotherapy or in combo with other oral antidiabetic agents or insulin - taken orally at mealtime - do not cause hypoglycemia when used alone - do not cause weight gain
79
Adverse effects of alpha-glycosidase inhibitors
- most common: malabsorption, flatulence, diarrhea, and abdominal bloating - hypoglycemia has been described when combined with insulin or insulin secretagogues
80
Drug interactions
-decrease absorption of digoxin and propranolol and ranitidine